Client News
Newron announces 2021 financial results and provides outlook for 2022
AYOXXA receives fresh capital for commercial growth in Europe, US and Asia led by Prosnav Capital
Abivax reports promising ABX464 phase 2a one-year maintenance results in rheumatoid arthritis
InflaRx Announces Vilobelimab Trial in Pyoderma Gangrenosum Selected for Late-Breaker Oral Presentation at 2022 AAD Annual Meeting
NEC OncoImmunity Acquires VAXIMM’s Neoantigen Vaccine Development Assets
AiCuris erhält NRW-Förderung von insgesamt EUR 5,9 Mio. für die Entwicklung seines Corona-Virus-Programms zur Vorbeugung schwerer Symptome bei SARS-CoV-2-Infektionen
RedHill Announces Positive Phase 2 Study Results with Oral RHB-107 in Non-Hospitalized COVID-19
InflaRx Provides Update on Development Plans for Vilobelimab in Hidradenitis Suppurativa
Heidelberg Pharma and Huadong Announce Strategic Partnership, Including Equity Investment
